88% of previous relapsers achieve hepatitis C cure with simeprevir-based triple therapy

Keith Alcorn
11 April 2014
Xavier Forns speaking at the International Liver Congress 2014. Photo by Liz Highleyman, hivandhepatitis.com.

Almost 90% of European patients who had relapsed after previous treatment with pegylated interferon and ribavirin were cured of hepatitis C after 24 weeks of treatment with the protease inhibitor simeprevir (Olysio) combined with pegylated interferon and ribavirin, the 49th Annual Meeting of the European Association for the Study of the Liver (EASL) heard on Thursday in London.

Simeprevir is a second-generation HCV protease inhibitor that is better tolerated than the first-generation protease inhibitors telaprevir (Incivo) and boceprevir (Victrelis). Simeprevir received marketing approval in the United States in November 2013 and a positive scientific opinion from the European Medicines Agency in March 2014. The European Medicines Agency is expected to grant European Union marketing approval for simeprevir in May or June 2014.

The data presented on the responses of European patients are derived from the PROMISE study, a randomised comparison of simeprevir or placebo, combined with pegylated interferon or ribavirin. The international study evaluated simeprevir-based triple therapy in treatment-experienced patients with hepatitis C virus (HCV) genotype 1. Results of the study were first released in May 2013.



An inherited gene which all individuals have. There are three genotypes of IL28B; these influence response to hepatitis C and its treatment. People with CC genotype are more likely to spontaneously clear acute infection or (during chronic infection) respond well to interferon-based treatment. The other two genotypes are known as CT and TT.

PROMISE recruited patients in both North America (30%) and Europe (70%). An analysis of European patients was carried out in order to determine the efficacy of simeprevir in a patient population with a very low prevalence of genotype 1a virus that carries the Q80K polymorphism. This naturally occurring variation in the virus reduces the efficacy of simeprevir, and was present in 48% of US patients with genotype 1a infection who participated in phase II studies of simeprevir. In contrast, only 5.5% of European participants in the PROMISE study who had genotype 1a infection had the Q80K polymorphism.

The US Food and Drug Administration has recommended that all patients with genotype 1a infection should be tested for the Q80K polymorphism to determine whether simeprevir treatment will be suitable.

A total of 393 people were recruited to this randomised, double-blind, placebo-controlled phase III study. All the participants had HCV genotype 1 and had relapsed after dual therapy with pegylated interferon/ribavirin.

Therapy in the treatment arm consisted of the protease inhibitor simeprevir (150mg once daily) for twelve weeks plus pegylated interferon/ribavirin for 24 or 48 weeks, according to treatment response. Individuals in the control arm received a placebo for twelve weeks plus pegylated interferon and ribavirin  for 48 weeks.

The primary outcome was sustained virological response twelve weeks after the completion of treatment (SVR12).

The study population was 65% male, 98% white, and 70.4% of participants had HCV genotype 1b infection.

Overall, 79% of participants in the PROMISE study receiving simeprevir achieved SVR12 compared to 36% of those in the placebo arm. Restricting analysis to European patients showed that SVR rates were 88% and 43% in the treatment and control arms, respectively.

Further analysis was restricted to the European patients taking simeprevir. Most (94%) were eligible for 24-weeks treatment with pegylated interferon/ribavirin and 91% of these patients achieved SVR12.

Impressive outcomes were observed among participants with stage F3 and F4 fibrosis who made up 28.7% of participants. 87% and 85% respectively achieved SVR12, compared with 88% of those with F0-F2 fibrosis.

Treatment outcomes did not differ greatly between patients with genotype 1a and 1b infection (88 vs 87%). As expected, SVR rates were higher among patients with the IL28B CC polymorphism, which responds better to interferon, compared to patients without this polymorphism (CC = 93% vs CT = 88% vs TT = 77%).

Response to simeprevir was reduced among the eight patients with genotype 1 infection and the Q80K polymorphism, although the number of patients was small. Six of the eight genotype 1a patients with the Q80K polymorphism achieved SVR12, compared to 90% of genotype 1a patients without the polymorphism. In comparison 87% of genotype 1b patients achieved SVR12.

There was no significant difference between the people taking simeprevir and the placebo group in the proportion of patients who experienced grade 3 or 4 serious adverse events. The majority of side-effects (80%) were mild to moderate. The most common adverse events were fatigue, headache and flu-like illness. Rash (20.7 vs 15.6%) and photosensitivity (4.3 vs 0%) occurred more frequently in the people taking simeprevir, as did influenza-like illness (29.9 vs 20%).


Forns X et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in European patients who relapsed after previous interferon-based therapy: the Promise Trial. 49th Annual Meeting of the European Association for the Study of the Liver (EASL), abstract 13, London, 2014.